Diagnostic and predictive value of urine PCA3 gene expression for the clinical management of patients with altered prostate-specific antigen

Rodón, Natàlia; Trias, Isabel; Verdú, Montse; Román, R.; Domínguez, A.; Calvo, Miquel; Banús, J.M.; Ballesta, Antonio M.; Maestro, M.L.; Puig, Xavier

doi:10.1016/j.acuroe.2013.11.012

Cited by 3 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…None of the patients with a positive s-PCA3 below 50 showed more than 33% of cylinders affected by PCa and 68.8% of them had a Gleason score below 7. In contrast, 76.8% of patients with ans-PCA3 over 50 had a Gleason score higher than or equal to 7.These results are in agreement with previously published data from reviews and meta-analyses and also confirm our previous results [11,16,28,29]. To our knowledge this is the first time that the relation between s-PCA3 and the new Grade Group has been explored.…”

Section: Discussionsupporting

confidence: 92%

“…Moreover, only a very weak significant relationship was found with patient age. Incorporation of the PCA3 study into PCa screening significantly reduced (by 54%) the indication for biopsy, in accordance with previously published data [11,17,26,27]. In patients with a positive s-PCA3, the percentage of positive biopsies was markedly increased (to 60.9%, including ASAP) compared with the percentage in biopsies indicated by PSA and DRE alone.…”

Section: Discussionsupporting

confidence: 89%

“…In contrast, the 76.8% of patients in our series with an s-PCA3 higher than 50 were assigned to Grade Groups 2-5, suggesting that a more aggressive therapeutic approach may be adequate. Considering all the results, in addition to the new evidence showing that a significant relationship between s-PCA3 and the Grade Group, it was confirmed that, as suggested by previous studies [11,17,28,29]. S-PCA3 has prognostic significance in prediction of the aggressiveness of PCa [11,17,28,29].…”

Section: Discussionsupporting

confidence: 85%

“…The s-PCA3 was considered positive when it was 35 or higher and only in these cases was a prostate biopsy recommended owing to the high probability of detecting PCa [15]. When the association between PCA3 and the parameters of tumor aggressiveness was analyzed, the s-PCA3 cut-off was established at 50, in accordance with previous studies [11,16,17].…”

Section: Pca3 Determinationmentioning

confidence: 79%

“…The purpose of this study was to evaluate the yield of PCA3 as an additional test in the management of patients with suspected PCa and to investigate whether our previously published results, in a prospective study of 598 patients, would be confirmed [11]. Moreover, the association of PCA3 with the new Grade Groups proposed by the International Society of Urological Pathology (ISUP) in 2014 was evaluated [12][13][14].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

A Low Score in Patients with a Positive PCA3 Urine Test Predicts the Lowest Prognostic Category in the New Grading System for Prostate Carcinoma

Rodón¹

2018

OAJCO

View full text Add to dashboard Cite

Purpose: In this study we evaluate the PCA3 as a tool to improve prostate cancer (PCa) screening and it's capability to predict PCa aggressiveness. Materials and Methods:This retrospective study included data from consecutive patients with suspected PCa who presented to the urology office between November 2009 and April 2016 and were candidates for prostate biopsy. A total of 1038 urine samples were tested in our laboratory with a kit that generated a PCA3 score (s-PCA3). A prostate biopsy was recommended only in those patients with s-PCA3 ≥ 35. Associations between variables were analyzed using the R software. Results:In patients with a positive s-PCA3 (44.5%), a subsequent biopsy was recommended. A total of 151 biopsies were studied, 56.3% yielded a diagnosis of PCa. The probability of a positive biopsy increased as the s-PCA3 increased (p=0.041). The percentage of affected cylinders increased as the s-PCA3 increased (p=0.015). A statistically significant relationship was observed between s-PCA3 and both the Gleason score and the Grade Group (p=0.001 and 0.008, respectively). The best log linear models and a logistic model confirmed the relationships shown previously with Fisher's exact tests.Conclusions: s-PCA3 may serve as an additional marker to reduce the indication for biopsies and avoid overdiagnosis and overtreatment of patients with suspected PCa. The prognostic significance of s-PCA3 was confirmed, as it was associated with tumor volume and Gleason score. Importantly, to our knowledge this is the first time that an association has been demonstrated between s-PCA3 and the new Grade Group.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 85%

Section: Pca3 Determinationmentioning

confidence: 79%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A Low Score in Patients with a Positive PCA3 Urine Test Predicts the Lowest Prognostic Category in the New Grading System for Prostate Carcinoma

Rodón¹

2018

OAJCO

View full text Add to dashboard Cite

show abstract

Le test urinaire PCA3 : quelles perspectives ?

Vlaeminck-Guillem

2014

Médecine Nucléaire

View full text Add to dashboard Cite

MicroRNA-940 as a Potential Serum Biomarker for Prostate Cancer

et al. 2021

View full text Add to dashboard Cite

Prostate cancer is one of the leading causes of death despite an astoundingly high survival rate for localized tumors. Though prostate specific antigen (PSA) test, performed in conjunction with digital rectal examinations, is reasonably accurate, there are major caveats requiring a thorough assessment of risks and benefits prior to conducting the test. MicroRNAs, a class of small non-coding RNAs, are stable molecules that can be detected in circulation by non-invasive methods and have gained importance in cancer prognosis and diagnosis in the recent years. Here, we investigate circulating miR-940, a miRNA known to play a role in prostate cancer progression, in both cell culture supernatants as well as patient serum and urine samples to determine the utility of miR-940 as a new molecular marker for prostate cancer detection. We found that miR-940 was significantly higher in serum from cancer patients, specifically those with clinically significant tumors (GS ≥ 7). Analysis of receiver operating characteristic curve demonstrated that miR-940 in combination with PSA had a higher area under curve value (AUC: 0.818) than the miR-940 alone (AUC: 0.75) for the diagnosis of prostate cancer. This study provides promising results suggesting the use of miR-940 for prostate cancer diagnosis.

show abstract

Diagnostic and predictive value of urine PCA3 gene expression for the clinical management of patients with altered prostate-specific antigen

Cited by 3 publications

References 21 publications

A Low Score in Patients with a Positive PCA3 Urine Test Predicts the Lowest Prognostic Category in the New Grading System for Prostate Carcinoma

A Low Score in Patients with a Positive PCA3 Urine Test Predicts the Lowest Prognostic Category in the New Grading System for Prostate Carcinoma

Le test urinaire PCA3 : quelles perspectives ?

MicroRNA-940 as a Potential Serum Biomarker for Prostate Cancer

Contact Info

Product

Resources

About